Stocks and Investing
Stocks and Investing
Fri, June 23, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Olivia Brayer Reiterated (VRTX) at Buy and Held Target at $365 on, Jun 23rd, 2023
Olivia Brayer of Cantor Fitzgerald, Reiterated "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $365 on, Jun 23rd, 2023.
Olivia has made no other calls on VRTX in the last 4 months.
There are 18 other peers that have a rating on VRTX. Out of the 18 peers that are also analyzing VRTX, 4 agree with Olivia's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Reiterated at Hold and Held Target at $323 on, Thursday, June 22nd, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $305 on, Tuesday, May 2nd, 2023
- Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $340 on, Tuesday, May 2nd, 2023
- Brian Skorney of "Baird" Maintained at Hold with Increased Target to $325 on, Tuesday, May 2nd, 2023
These are the ratings of the 14 analyists that currently disagree with Olivia
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $380 on, Monday, June 12th, 2023
- Myles Minter of "William Blair" Initiated at Buy on, Tuesday, May 30th, 2023
- Christopher Raymond of "Piper Sandler" Initiated at Buy and Held Target at $385 on, Thursday, May 4th, 2023
- Jason McCarthy of "Maxim Group" Maintained at Strong Buy with Increased Target to $400 on, Wednesday, May 3rd, 2023
- William Pickering of "Bernstein" Maintained at Buy with Increased Target to $363 on, Wednesday, May 3rd, 2023
- Jessica Fye of "JP Morgan" Maintained at Buy and Held Target at $345 on, Tuesday, May 2nd, 2023
- Phil Nadeau of "TD Cowen" Maintained at Buy with Increased Target to $350 on, Tuesday, May 2nd, 2023
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $456 on, Tuesday, May 2nd, 2023
- Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $399 on, Tuesday, May 2nd, 2023
- Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $385 on, Tuesday, May 2nd, 2023
- Evan Seigerman of "BMO Capital" Maintained at Buy and Held Target at $385 on, Tuesday, May 2nd, 2023
- Gena Wang of "Barclays" Maintained at Buy with Increased Target to $384 on, Tuesday, May 2nd, 2023
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $410 on, Tuesday, May 2nd, 2023
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $350 on, Wednesday, March 29th, 2023
Contributing Sources